ClinicalTrials.gg
RecruitingNCT07535099Updated Jun 18, 2026

Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in Healthy Subjects

A Phase 1 interventional study of ICP-538 Tablets and ICP-538 placebo Tablets in Health Services Research, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This is a Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in Healthy Subjects

02

Conditions studied

  • Health Services Research
03

In context

Lead sponsor

Beijing InnoCare Pharma Tech Co., Ltd. is the lead sponsor of 61 studies on the registry; 37 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the ICF..
  2. between 18-26 kg/m² (inclusive). Male weight ≥50 kg; female weight ≥45 kg.
  3. Vital signs, physical examination, , Chest X-ray, Abdominal ultrasound results at screening are within normal range or showing minor deviations deemed not by the investigator.
  4. Laboratory test results at screening and baseline are within the normal reference range.
  5. Reproductive Status:Females of non- . Male participants and their partners must agree to use effective throughout the study and for 3 months after the last dose. Male participants must not donate sperm during this period.

Exclusion criteria

Exclusion Criteria:

  1. Evidence or history of diseases, or Evidence or history of allergic diseases .
  2. Clinically significant gastrointestinal dysfunction that may affect drug intake, transport, or absorption.
  3. Acute illness within 14 days before dosing.
  4. Severe infection within 6 months before dosing, or chronic/recurrent infections.
  5. Participant and/or first-degree relative with hereditary immunodeficiency.
  6. Major trauma or surgery within 3 months before dosing.
  7. History of active/latent TB or contact with an open TB case within 6 months before dosing.
  8. Positive urine drug screen.
  9. Alcohol abuse.
  10. Use of tobacco/nicotine products within 3 months before the first dose.
  11. Use of any prescription/non-prescription drugs, herbal medicines, supplements within 14 days before first dose; or systemic , /modulators, hormone replacement therapy within 30 days before first dose; or any other factor affecting drug absorption, distribution, metabolism, and excretion.
  12. Consumption of caffeine-containing foods/beverages within 48 hours before the first dose.
  13. Use of known inducers/inhibitors within 14 days or 5 half-lives (whichever is longer) before the first dose.
  14. Dieting, dietary therapy within 30 days before the first dose.
  15. Positive for syphilis antibody, -Ab, , HBcAb, or -Ab at screening.
  16. Administration of within 6 weeks before the first dose or planned during study or within 8 weeks after study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    Single ascending doses of ICP-538 tablet

    Drug: ICP-538 Tablets

  • Experimental
    Multiple ascending doses of ICP-538 tablet

    Drug: ICP-538 Tablets

  • Placebo comparator
    Single ascending doses of placebo

    Drug: ICP-538 placebo Tablets

  • Placebo comparator
    Multiple ascending doses of placebo

    Drug: ICP-538 placebo Tablets

Interventions

  • DrugICP-538 Tablets

    ICP-538 will be administered as tablet

  • DrugICP-538 placebo Tablets

    Matching placebo will be administered as tablet

06

What researchers measure

Primary outcomes

  1. Treatment-emergent adverse events (TEAEs)

    Incidence and severity of treatment-emergent adverse events (TEAEs).

    Time frame: Up to 7 weeks

  2. The incidence and severity of abnormal clinical laboratory tests

    Incidence and severity of clinically significant laboratory test abnormalities during treatment (including hematology, biochemistry, urinalysis, stool routine, etc.).

    Time frame: Up to 7 weeks

  3. The incidence of abnormalities in vital signs, physical examination, 12-lead ECG, etc.

    The incidence of abnormalities in vital signs, physical examination, 12-lead ECG, etc.

    Time frame: up to 7 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Sep 2026, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2026
First posted
Apr 16, 2026
StartActual
Mar 13, 2026
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07535099
Responsible party
Sponsor
First posted
Apr 16, 2026
Start date
Mar 13, 2026
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Jun 18, 2026

Study contacts

Quankun Zhuang
Contact
zhuangqk@gobroadhealthcare.com
+86-13011825339

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion